Development and validation of a stability indicating rp-hplc method for simultaneous determination of haloperidol and benzhexol in pharmaceutical combined dosage forms

The study describes development and subsequent validation of a stability indicating reverse-phase HPLC method for simultaneous estimation of the Haloperidol and Benzhexol in combined Pharmaceutical dosage form using RP-HPLC. Separation was accomplished on BDS 250 x 4.6 mm, 5mm C18 column using 0.1% OPA buffer and acetonitrile (45:55 v/v) as mobile phase pumped through at a flow rate of 1 ml/min  at 30°C. Optimized wavelength was 210 nm, retention time of Haloperidol and Benzhexol were found to be 2.3 min and 2.7 min respectively. % RSD of the Haloperidol and Benzhexol were found to be 1.1 and 0.8 respectively. Mean recovery were found to be 99.97% and 99.94% for Haloperidol and Benzhexol respectively. The proposed method also proved to be suitable as a rapid and reliable quality control method.